Amylin Pharmaceuticals, Inc. (AMLN) announced new clinical data from the European Exenatide or EUREXA study that showed treatment with BYETTA injection resulted in greater glycemic durability and overall glycemic control than Amaryl in patients with type 2 diabetes uncontrolled on metformin alone.
The company also noted that patients treated with BYETTA have experienced reductions in body weight and fewer hypoglycemic events.
The company said these clinical study findings are being presented at the 2012 ADA/The Lancet Symposium at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia and will be published in the diabetes-themed issue of The Lancet.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.